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1. INTRODUCTION  
A drug may be defined as a substance meant for diagnosis, cure, prevention, or treatment of 
diseases in human beings or animals or for alternating any structure or function of the body of 
human being or animals. 
Analytical method development and validation play important roles in the drug discovery, 
development, and manufacture of pharmaceuticals. 
This presentation will discuss the development and validation of analytical method (High 
performance liquid chromatography (HPLC), High performance thin layer chromatography 
(HPTLC)) for drug products. 
The number of drugs introduced into market is increasing every year. These drugs may be 
either new entities or partial structural modification of the existing one. Very often there is a 
time lag from the date of introduction of a drug into the market to the date of its inclusion in 
pharmacopoeias. This happens because of the possible uncertainties in the continuous and 
wider usage of these drugs, report of new toxicities (resulting in their withdrawal from the 
market), and development of patient resistance and introduction of better drugs by 
competitors. Under these conditions, standards and analytical procedures of these drugs may 
not be available in the pharmacopoeias. It becomes necessary, therefore to develop newer 
analytical methods for such drugs. 
Basic Criteria for New Method Development of Drug Analysis1: 
¾ The drug may not be official in any pharmacopoeias. 
¾ A proper analytical procedure for the drug may not be available in the literature due to 
patent regulations. 
¾ Analytical methods may not be available for the drug in the form of a formulation due 
to the interference caused by the formulation excipients. 
¾ Analytical methods for the quantitation of the drug in biological fluids may not be 
available. 
Introduction to HPLC method of analysis for drug: 
Most of the drugs dosage forms can be analysed by HPLC method because of the several 
advantages like rapidity, specificity, accuracy, precision and ease of automation in this 
method. 
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Some of the advantages are: 
¾ Speed (analysis can be accomplished in 20 minutes or less), 
¾ Greater sensitivity (various detectors can be employed), 
¾ Improved resolution (wide variety of stationary phases), 
¾ Reusable columns (expensive columns but can be used for many analysis), 
¾ Ideal for the substances of low volatility, 
¾ Easy sample recovery, handling and maintenance, 
¾ Instrumentation tends itself to automation and quantitation (less time and less labour), 
¾ Precise and reproducible, 
¾ Calculation are done by integrator itself, 
¾ Suitable for preparative liquid chromatography on a much larger scale. 
Chromatographic methods are commonly used for the quantitative and qualitative analysis of 
raw materials, drug substances, drug products and compounds in biological fluids2. 
TYPES OF CHROMATOGRAPHY3-6: 
Chromatography is a technique by which the components in a sample, carried by the liquid or 
gaseous phase, are resolved by sorption- desorption steps on the stationary phase. 
A. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC): 
High performance liquid chromatography separation based on interaction and differential 
partition of the sample between the mobile liquid phase and the stationary phase. The 
commonly used chromatographic methods are divided into the following groups, 
1. Normal phase 
2. Reverse phase 
3. Chiral 
4. Ion exchange 
5. Ion pair 
6. Affinity 
7. Size exclusion 
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1. NORMAL PHASE CHROMATOGRAPHY: 
In the normal phase mode, the stationary phase is polar and the mobile phase is nonpolar in 
nature. In this technique, nonpolar compounds travel faster and are eluted first. This is 
because of the lower affinity between the nonpolar compounds and the stationary phase. 
Polar compounds are retained for longer times because of their higher affinity with the 
stationary phase. These compounds, therefore take more times to elute. Normal phase mode 
of separation is therefore, not generally used for pharmaceutical application because most of 
the drug molecules are polar in nature and hence take longer time to elute. 
2. REVERSE PHASE CHROMATOGRAPHY: 
Reversed phase mode is the most popular mode for analytical and preparative separations of 
compound of interest in chemical, biological, pharmaceutical, food and biomedical sciences. 
In this mode, the stationary phase is nonpolar hydrophobic packing with octyl or octa decyl 
functional group bonded to silica gel and the mobile phase is polar solvent. An aqueous 
mobile phase allows the use of secondary solute chemical equilibrium (such as ionization 
control, ion suppression, ion pairing and complexation) to control retention and selectivity. 
The polar compound gets eluted first in this mode and nonpolar compounds are retained for 
longer time. As most of the drugs and pharmaceuticals are polar in nature, they are not 
retained for longer times and hence elute faster. The different columns used are octa decyl 
silane (ODS) or C18, C8, C4, etc; (in the order of increasing polarity of the stationary phase). 
3. CHIRAL PHASE CHROMATOGRAPHY: 
Separation of the enantiomers can be achieved by on chiral stationary phases by formation of 
diastereomers via derivating agents or mobile phase additives on achiral stationary phases. 
When used as an impurity test method, the sensitivity is enhanced if the enantiomeric 
impurity elutes before the enantiomeric drug. 
4. ION EXCHANGE CHROMATOGRAPHY: 
In ion exchange chromatography, the stationary phase contains ionic groups like NR3+or SO3- 
which interact with the ionic groups of the sample molecules. This is suitable for the 
separation of charged molecules only. Changing the pH and salt concentration can modulate 
the retention. 
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5. ION PAIR CHROMATOGRAPHY: 
Ion pair chromatography may be used for the separation of ionic compounds and this method 
can also substitute for ion exchange chromatography. Strong acidic and basic compounds 
may be separated by reversed phase mode by forming ion pairs with suitable counter ions. 
This technique is referred to as reversed phase ion pair chromatography. 
6. AFFINITY CHROMATOGRAPHY: 
Affinity chromatography uses highly specific biochemical interactions for separation. The 
stationary phase contains specific groups of molecules which can absorb the sample if certain 
steric and charge related conditions are satisfied. This technique can be used to isolate 
proteins, enzymes as well as antibodies from complex mixtures. 
7. SIZE EXCLUSION CHROMATOGRAPHY: 
Size exclusion chromatography separates molecules according to their molecular mass. 
Largest molecules are eluted first and the smallest molecules last. This method is generally 
used when a mixture contains compounds with a molecular mass difference of at least 10%. 
This mode can be further subdivided into gel permeation chromatography (with organic 
solvents) and gel filtration chromatography (with aqueous solvents). 
                          SCHEMATIC DIAGRAM OF HPLC EQUIPMENT7 
 
 
In HPLC the mobile phase acts as a carrier for the sample solution. A sample solution is 
injected into the mobile phase through the injector port. As the sample solution flows through 
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a column with the mobile phase, the components of that solution migrate according to the 
non-covalent interaction of the compound with the column; determine the degree of 
migration and separation of components contained in the sample. The mobile phase can be 
altered in order to manipulate the interactions of the sample and the stationary phase. There 
are several types of elution namely: isocratic, gradient, and polytypic. 
IN ISOCRATIC ELUTION: 
Isocratic elution compounds are eluted using constant mobile phase composition all 
compounds begin migration through the column at onset. However each migrates at a 
different rate, resulting in faster or slower elution rate. This type of elution is both simple and 
inexpensive, but resolution of some compounds is questionable and elution may not be 
obtained in a reasonable amount of time. 
IN GRADIENT ELUTION: 
Gradient elution different compounds are eluted by increasing the strength of the organic 
solvent. The sample is injected while a weaker mobile phase is being applied to the system. 
The strength of the mobile phase is later increased in increments by raising the organic 
solvent fraction, which subsequently results in elution of retained components. This is usually 
done in a stepwise or linear fashion. 
COMPONENTS OF HPLC8-11: 
¾ Solvent delivery system 
¾ Pump 
¾ Sample injection system 
¾ Column 
¾ Detector 
¾ Recorder 
A. SOLVENT DELIVERY SYSTEM: 
A mobile phase is pumped pressure from one or several reservoir and flows through the 
column at a constant rate. For normal phase separation eluting power increases with 
increasing polarity of the solvent but for reversed phase separation, eluting power decreases 
with increasing polarity. 
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A degasser is needed to remove dissolved air and other gases from the solvent. Special grades 
of solvents are available for HPLC and these have been purified carefully in order to remove 
absorbing impurities and particulate matter to prevent these particles from damaging the 
pumping or injection system or clogging the column. 
PUMPS: 
The pump is one of the most important component of HPLC, since its performance directly 
affects retention time, reproducibility and detector sensitivity. 
Three main types of pumps are used in HPLC to propel the liquid mobile phase through the 
system. 
1. DISPLACEMENT PUMP: It produces a flow that tends to independent of viscosity and 
back pressure and also output is pulse free. But is possesses limited capacity (250 ml). 
2. RECIPROCATING PUMP: It has small internal volume (35 to 400µl), their high output 
pressure (up to 10,000 psi) and their constant flow rates. But it produces a pulsed flow. 
3. PNEUMATIC OR CONSTANT PRESSURE PUMP: They are pulse free, suffer from 
limited capacity as well as a dependence of flow rate on solvent viscosity and column back 
pressure. They are limited to pressure less than 2000 psi. 
B. SAMPLE INJECTION SYSTEM: 
Insertion of the sample onto the pressurized column must be as a narrow plug so that the peak 
broadening attributable to this step is negligible. The injection system itself should have no 
dead (void) volume. 
There are three important ways of introducing the sample into injection port. 
1. LOOP INJECTION: 
In which, a fixed amount of volume is introduced by making use of fixed volume loop 
injector. 
2. VALVE INJECTION: 
In which, a variable is introduced by making use of an injection valve. 
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3.  COLUMN INJECTION: 
In which, a variable volume is introduced by means of a syringe through a septum. 
C. CHROMATOGRAPHIC COLUMN: 
The column is usually made up of heavy glass or stainless steel tubing to withstand high 
pressure. The columns are usually 10-30 cm long and 4-10 mm inside diameter containing 
stationary phase at particle diameter of 25 µm or less. Columns with an internal diameter of 
5mm give good results because of compromise between efficiency, sample capacity, and the 
amount of packing and solvent required. 
COLUMN PACKING: 
The packing used in modern HPLC consist of small, rigid particles having an arrow particle 
size distribution. There are three main types of column packing in HPLC. 
1. POROUS, POLYMERIC BEDS: 
Porous, polymeric beds based on styrene divinely benzene co-polymers used. For analytical 
purpose these have now been replaced by silica based, packing which are more efficient and 
more stable. 
2. POROUS LAYER BEDS: 
Consisting of a thin shell (1-3µm) of silica or modified silica on an spherical inert core (e.g. 
glass). After the development of totally porous micro particulate packing, these have not been 
used in HPLC. 
3. TOTALLY POROUS SILICA PARTICLES (dia. 10 µm): 
These packing have widely been used for analytical HPLC in recent years. Particles of 
diameter  20µm are usually dry packed. While particles of diameter  20µm are slurry 
packed in which particles are suspended on a suitable solvent and the slurry so obtained is 
driven into the column under pressure. 
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D. DETECTORS: 
The function of the detector in HPLC is to monitor the mobile phase as it merges from the 
column. Detectors are usually of two types. 
1. BULK PROPERTY DETECTORS: 
It compares overall changes in a physical property of the mobile phase with and without an 
eluting solute. E.g.  Refractive index, Dielectric constant or Density. 
2. SOLUTE PROPERTY DETECTORS: 
It responds to a physical property of the solute which is not exhibited by the pure mobile 
phases. E.g. UV absorbance, Fluorescence or diffusion current. Such detectors are about 1000 
times more sensitive giving a detectable signal for a few nano grams of sample. 
METHOD DEVELOPMENT BY HPLC12-14: 
Method for analysing drug dosage form can be developed, depend upon the 
¾ Nature of the sample 
¾ Molecular weight 
¾ Polarity 
¾ Ionic character 
¾ Solubility 
In general one begins with reversed phase chromatography, when the compounds are 
hydrophilic in nature with many polar groups and are water soluble. The organic phase 
concentration required for the mobile phase can be estimated by gradient elution method. For 
aqueous sample mixtures, the best way to start is with gradient reverse phase 
chromatography. Gradient can be started with 5-10 % organic phase in the mobile phase and 
the organic phase concentration (methanol or acetonitrile) can be increased up to 100% 
within 30-45 min. 
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 The various parameters for method development. 
1. Mode of separation 
2. Selection of stationary phase 
3. Selection of mobile phase 
4. Selection of detector 
1. SELECTION OF MODE OF SEPARATION: 
In reverse phase mode, the mobile phase is comparatively more polar than the stationary 
phase. For the separation of polar or moderately polar compounds, the most preferred mode is 
reverse phase. The nature of the analyte is the primary factor in the selection of the mode of 
separation. A second factor is the nature of the matrix. 
2. SELECTION OF STATIONARY PHASE / COLUMN: 
Selection of the column is the first and the most important step in method development. The 
appropriate choice of separation column includes three different approaches 
1. Selection of separation system 
2. The particle size and the nature of the column packing. 
3. The physical parameters of the column i.e. the length and the diameter. 
Some of the important parameters considered while selecting chromatographic columns are 
¾ Length and diameter of the column. 
¾ Packing material 
¾ Shape of the particles 
¾ Size of the particles 
¾ Percentage of carbon loading 
¾ Pore volume 
¾ Surface area 
¾ End capping 
The column is selected depending on the nature of the solute and the information about the 
analyte. Reversed phase mode of chromatography facilitates a wide range of columns like 
dimethyl silane  (C2), butyl silane (C4), octyl silane (C8), octadecyl silane  (C18), base 
deactivated silane (C18) BDS phenyl, cyanopropyl (CN), nitro, amino etc. C18 was chosen for 
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this study. Generally longer columns provide better separation due to higher theoretical plate 
numbers. As the particle size decreases the surface area available for coating increases. 
Column with 5µm particle size give the best compromise of efficiency, reproducibility and 
reliability. In this case the column selected had a particle size of 5 µm and a internal diameter 
of 4.6mm 
Peak shape is equally important in method development. Columns that provide symmetrical 
peaks are always preferred while peaks with poor asymmetry can result in 
¾ In accurate plate number and resolution measurement 
¾ Imprecise quantitation 
¾ Degraded and undetected minor bands in the peak tail 
¾ Poor retention reproducibility 
A useful and practical measurement of peak shape is peak asymmetry factor and peak tailing 
factor. Peak asymmetry is measured at 10% of full peak height and peak tailing factor at 5%. 
Reproducibility of retention time and capacity factor is important for developing a rugged 
and repeatable method. A column which gives separation of all the impurities and degrades 
from each other and from analyte peak and which is rugged for variation in mobile phase 
shall be selected. 
3. SELECTION OF MOBILE PHASE: 
The primary objective in selection and optimization of mobile phase is to achieve optimum 
separation of all the individual impurities and degrades from each other and from analyte 
peak. 
In liquid chromatography, the solute retention is governed by the solute distribution factor, 
which reflects the different interactions of the solute-stationary phase, solute-mobile phase 
and the mobile phase-stationary phase. For a given stationary phase, the retention of the given 
solute depends directly upon the mobile phase, the nature and the composition of which has 
to be judiciously selected in order to get appropriate and required solute retention. The 
mobile phase has to be adopted in terms of elution strength (solute retention) and solvent 
selectivity (solute separation). 
Solvent polarity is the key word in chromatographic separations. Since a polar mobile phase 
will give rise to low solute retention in normal phase and high solute retention in reverse 
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phase LC. The selectivity will be particularly altered if the buffer pH is close to the pKa of 
the analytes. The solvent strength is a measure of its ability to pull analyte from the column. 
It is generally controlled by the concentration of the solvent with the highest strength .The 
following parameters, which shall be taken into consideration while selecting and optimizing 
the mobile phase. 
¾ Buffer 
¾ pH of the buffer 
¾ Mobile phase composition 
3.1. Buffer: 
Buffer and its strength play an important role in deciding the peak symmetries and 
separations. Some of the most common buffers are 
¾ Phosphate buffers prepared using salts like K2HPO4, K2HPO4, NaH2PO4, Na2HPO4, 
etc. 
¾ Phosphoric acid buffer using H3PO4 
¾ Acetate buffers – Ammonium Acetate, Sodium Acetate, etc. 
¾ Acetic acid buffers using CH3COOH. 
The retention time also depend on the molar strength of the buffer. Molar strength is 
increasingly proportional to retention time. 
3.2. pH of the buffer: 
pH plays an important role in achieving the chromatographic separations as it controls the 
elution properties by controlling the ionization characteristics. To maintain the pH of the 
mobile phase in the range of 2.0 to 8.0 as most columns does not withstand to the pH which 
are outside this range. This is due to the fact that the siloxane linkage are cleaved below pH 
2.0, while the pH value above 8.0 silica may dissolve. 
3.3. MOBILE PHASE COMPOSITION: 
Most chromatographic separations can be achieved by choosing the optimum mobile phase 
composition. This is due to the fact that fairly large amount of selectivity can be achieved by 
choosing the qualitative and quantitative composition of aqueous and organic portions. Most 
widely used solvent in reverse phase chromatography are methanol and acetonitrile. 
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Experiments were conducted with mobile phases having buffers with different pH and 
different organic phases to check for the best separations between the impurities. 
       A mobile phase which gives separation of all the impurities and degrades from the each 
other and from analyte peak and which is rugged for variation of both aqueous and organic 
phase by at least ± 0.2% of the selected mobile phase composition. 
SYSTEM SUITABILITY TESTS FOR CHROMATOGRAPHIC METHODS15-17: 
System suitability is the checking of a system to ensure system performance before or during 
analysis of unknowns. 
System suitability parameters and Recommendations: 
SL.NO PARAMETERS RECOMMENDATIONS 
1. Capacity factor (k´) The peak should be well resolved from other 
peaks and the void volume, generally k´  2.0. 
2. Repeatability RSD  / = 1% for N / = 5 is desirable. 
3. Relative retention Not essential as long as the resolution is stated. 
4. Resolution (Rs) RS of   2 between the peak of interest and the 
closest eluting potential interfere (impurity, 
excipient, degradation product, internal standard, 
etc. 
5. Tailing factor (T) T of  / = 2 
6. Theoretical plates (N) In general should be   2000 
 
The parameters that are affected by the changes in chromatographic conditions are: 
¾ Resolution (RS), 
¾ Capacity factor (k´), 
¾ Selectivity (a), 
¾ Column efficiency (N), 
¾ Peak asymmetry factor (AS). 
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1. RESOLUTION (RS): 
Resolution is the parameter describing the separation power of the complete chromatographic 
system relative to the particular components of the mixture. The resolution of two 
neighbouring peak is defined as the ratio of the distance between two peak maxima. It is the 
difference between the retention times of two solutes divided by their average peak width. 
For baseline separation, the ideal value of  RS  is 1.5. It is calculated by using the formula, 
 
Where Rt1 and Rt2 are the retention times of components 1 and 2 
W1 and W2  are peak width of components 1 and 2. 
2. CAPACITY FACTOR (K´): 
Capacity factor is the ratio of the reduced retention volume to the dead volume. Capacity 
factor, k´, is defined as the ratio of the number of molecules of solute in the stationary phase 
to the number of molecules of the same in the mobile phase. Capacity factor is a measure of 
how well the sample molecule is retained by a column during an isocratic separation. The 
ideal value of  k´ ranges from 2-10. Capacity factor can be determined by using the formula. 
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Where, tR = Retention volume at the apex of the peak (solute ) and 
to = void volume of the system. 
3. SELECTIVITY (A) : 
The selectivity (or separation factor) is a measure of relative retention of two components in a 
mixture. Selectivity is the ratio of the capacity factors of both peaks, and the ratio of the 
capacity factors of both peaks, and the ratio of its adjusted retention times. Selectivity 
represents the separation power of particular adsorbent to the mixture of these particular 
components. 
This parameter is independent of the column efficiency, it only depends on the nature of the 
components, elute type, and eluent composition and adsorbent surface chemistry. In general, 
if the selectivity of two components is equal to 1, then there is no way to separate them by 
improving the column efficiency. The ideal value of a is 2. 
 
It can be calculated by using formula, 
a = V2 – V1 / V1 – V0  =  K1´ / K2´ 
Where,         V0   =  The void volume of the column, 
V1 and V2  =   The retention volumes of the second and the first peak respectively. 
4. COLUMN EFFICIENCY / BAND BROADENING (N) : 
Efficiency of a column is measured by the number of theoretical plates per meter. It is a 
measure of band spreading of a peak. Similar the band spread, higher is the number of 
theoretical plates, indicating good column and system performance. Columns with N ranging 
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from 5000 to 100,000 plates/ meter are ideal for a good system. Efficiency is calculated by 
using the formula, 
 
Where,   tR  is the retention time and 
W is the peak width. 
5. PEAK ASYMMETRY FACTOR (TF): 
Peak asymmetry factor can be used as a column performance. The peak half width ‘b’ of a 
peak at 10% of the peak height, divided by the corresponding front half width ‘a’ gives the 
asymmetry factor. For a well packed column, an asymmetry factor of 0.9 to 1.1 should be 
achievable. 
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INTRODUCTION TO HPTLC METHODS OF ANALYSIS FOR DRUGS18-20 
HPTLC (High Performance Thin Layer Chromatography) is a well known and versatile 
separation method which shows a lot of advantages in comparison to other separation 
techniques. 
Layer of Sorbent 100µm 
Efficiency High due to smaller particle size generated 
Separations 3-5 cm 
Analysis time Shorter migration distance and the analysis 
time is greatly reduced 
Solid support Wide choice of stationary phases like silica 
gel for normal phase for reversed phase 
modes 
Development chamber New type that require less amount of mobile 
phase 
Sample spotting Auto sampler 
Scanning Use of UV/Visible/Fluorescence scanner 
scans the entire chromatogram qualitatively 
and quantitatively and the scanner is an 
advanced type of densitometer. 
 
FEATURES OF HPTLC: 
1. Simultaneous processing of sample and standard-better analytical precision and 
accuracy less need for internal standard. 
2. Several analysts work simultaneously 
3. Lower analysis time and less cost per analysis. 
4. Low maintenance cost. 
5. Simple sample preparation-handle samples of divergent nature. 
6. No prior treatment for solvents like filtration and degassing. 
7. Low mobile phase consumption per sample. 
8. No interference from previous analysis-fresh stationary and mobile phases for each 
analysis-no contamination. 
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9. Visual detection possible-open system. 
10.  Non UV absorbing compounds detected by post-chromatographic derivatization. 
STEPS INVOLVED IN HPTLC: 
1. Selection of chromatographic layer 
2. Sample and standard preparation 
3. Layer pre-washing 
4. Layer pre-conditioning 
5. Application of sample and standard 
6. Chromatographic development 
7. Detection of spots 
8. Scanning 
9. Documentation of chromatic plate 
SELECTION OF CHROMATOGRAPHIC LAYER: 
- Precoated plated-different support materials- different sorbents available. 
- 80% of analysis – silica gel GF. Basic substances, alkaloids and steroids       
aluminium oxide.  Amino acids, dipeptides, sugars and alkaloids- cellulose. 
- Non-polar substances, fatty acids, carotenoids, cholesterol – RP2, RP8 and RP 18. 
- Preservatives, barbiturates, analgesic and phenothiazine - Hybrid plates -        
RPWF254s. 
SAMPLE AND STANDARD PREPARATION: 
- To avoid interference from impurities and water vapours. 
- Low signal to noise ration- Straight base line- Improvement of LOD. 
- Solvents used are Methanol, Chloroform: Methanol (1:1), Ethyl acetate: Methanol 
(1:1), Chloroform: Methanol: Ammonia (90:9:1), Methylene chloride: Methanol 
(1:1), 1% Ammonia or 1% Acetic acid. 
- Dry the plates and store in dust free atmosphere. 
ACTIVATION OF PRE-COATED PLATES: 
- Freshly open box of plates do not require activation. 
- Plates exposed to high humidity or kept on hand for long time to be activated. 
- By placing in an oven at 110-120°C for 30’ prior to spotting. 
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- Aluminium sheets should be kept in between two glass plated and placing in oven at 
110-120°C for 15 minutes. 
APPLICATION OF SAMPLE AND STANDARD: 
- Usual concentration range is 0.1-1µg/µl. 
- Above this causes poor separation. 
- Linomat IV (automatic applicator) - nitrogen gas sprays sample and standard from 
syringe on TLC plates as bands. 
- Band wise application – better separation – high response to densitometer. 
SELECTION OF MOBILE PHASE: 
- Trial and error 
- One’s own experience and literature 
NORMAL PHASE 
- Stationary phase is polar 
- Mobile phase is non polar 
- Non polar compounds eluted first because of higher affinity with the stationary phase 
REVERSE PHASE 
- Stationary phase is non polar 
- Mobile phase is polar 
- Polar compounds eluted first because of lower affinity with stationary phase 
- Non–polar compounds retained because of higher affinity with the stationary phase. 
- 3-4 component mobile phase should be avoided. 
- Multi component mobile phase once used not recommended for further use and 
solvent composition is expressed by volumes (v/v) and sum of volumes is usually 
100. 
- Twin trough chambers are used only 10 – 15 ml of mobile phase is required 
- Components of mobile phase should be mixed introduced into the twin – trough 
chamber. 
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PRE- CONDITIONING (CHAMBER SATURATION): 
- Un saturation chamber causes high Rf  values 
- Saturated chamber by lining with filter paper for 30 minutes prior to development. 
- Uniform distribution of solvent vapours. 
- Less solvent for the sample to travel. 
- Lower Rf values. 
CHROMATOGRAPHIC DEVELOPMENT AND DRYING: 
- After development, remove the plate and mobile phase is removed from the plate. 
- To avoid contamination of lab atmosphere. 
- Dry in vacuum desiccator. 
- Avoid hair drier. 
- Essential oil components may evapourate. 
DETECTION AND VISUALIZATION: 
- Detection under UV light is first choice. 
- Non-destructive. 
- Spots of fluorescent compounds can been. 
- Fluorescent stationary phase is used. 
- Silica gel GF. 
- Non UV absorbing compounds like ethambutol, dicyclomine etc. 
- Dipping the plates in 0.1 % iodine solution. 
- When individual component does not respond to UV. 
- Derivatisation required for detection. 
QUANTIFICATION: 
- Sample and standard should be chromatographed on same plate. 
- After development chromatogram is scanned. 
- Camag TLC scanners III scan the chromatogram in reflectance or in transmittance 
mode by absorbance or by fluorescent mode. 
- Scanning speed is selectable up to 100 mm/s. 
- A spectrum recording is fast. 
- 36 tracks with up to 100 peak windows can be evaluated. 
Introduction  
 
Department Of Pharmaceutical Analysis, RVS College Of Pharmaceutical Sciences Page 20 
 
- Calibration of single and multiple levels with linear or non- linear regressions are 
possible when target values are to be verified such as stability testing and dissolution 
profile single level calibration is suitable 
- Statistics such as RSD or CI report automatically. 
- Concentration of analyte in the sample is calculated by considering the sample 
initially taken and dilution factors. 
                           
                            Fig.No: 2  SCHEMATIC PROCEDURE FOR HPTLC 
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HPTLC Method design and development 
Set the analytical objective first that may be quantification or qualitative identification or 
optimization of analysis time before starting HPTLC. Method for analyzing drugs dosage 
forms by HPTLC demands primary knowledge about the 
 
¾ Nature of the sample, 
¾ Namely, structure, 
¾ Polarity, 
¾ Volatility, 
¾ Stability, 
¾ Solubility. 
An exact recipe for HPTLC, however, also same like HPLC cannot be provided because 
method development involves considerable trial and error procedures.  The most difficult 
problem usually is where to start, with what kind of mobile phase. 
Selection of stationary phase is quite easy that is to start with silica gel which is reasonable 
and nearly suits all kinds of drugs. Mobile phase optimization is carried out by using three 
level techniques. First level involves use of neat solvents and then by finding some solvents 
which can have average separation power for the desired drugs. Second level involves 
decreasing or increasing solvent strength using hexane or water for respective purposes. 
Third level involves trying of mixtures instead of neat solvents from the selected solvents of 
first and second level which can further be optimized by the use of modifier like acids or 
bases. 
Analytes are detected using fluorescence mode or absorbance mode. But if the analytes are 
not detected perfectly than it need change of stationary phase or mobile phase or need the 
help of pre or post chromatographic derivatization. Optimization can be started only after a 
reasonable chromatogram which can be done by slight change in mobile phase composition. 
This leads to a reasonable chromatogram which has all the desired peaks in symmetry and 
well separated. 
Parameters that are affected by the changes in chromatographic conditions are: 
¾ Retention factor (Rf), 
¾ Peak purity, 
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1. RETENTION FACTOR (RF): 
Retention factor is defined as the amount of separation due to the solvent migration through 
the sorbent layer as shown in the formula.  It depends upon the time of development and 
velocity coefficient or solvent front velocity. 
 
                                                         Migration distance of substance 
                        Rf         =          -------------------------------------------------------- 
                                                Migration distance of solvent front from origin 
2. PEAK PURITY: 
The null hypothesis “these spectra are identical” can in this case (purity) with two sided 
significance. During the purity test the spectrum taken at the first peak slope is correlated 
with the spectrum of peak maximum [r(s, m)] and the correlation of the spectra taken at peak 
maximum with the one from the down slope or peak end [r(m, e)] which is used as a 
reference spectra for statistical calculation.  An error probability of 1% only is rejected if the 
test value is greater than or equal to 2.576. 
VALIDATION OF ANALYTICAL METHOD21-23: 
Validation is an act of providing that any procedure, process, equipment, material, activity or 
system performs as expected under given set of conditions and also give the required 
accuracy, precision, sensitivity, ruggedness, etc. 
The various validation parameters are: 
¾ Accuracy 
¾ Precision (repeatability and reproducibility), 
¾ Linearity and range, 
¾ Limit of detection (LOD) 
¾ Limit of quantification (LOQ) 
¾ Selectivity / specifity, 
¾ Robustness / ruggedness 
¾ Stability and system suitability studies. 
 
1. Accuracy: 
The accuracy of an analytical method may be defined as the closeness of the test results 
obtained by the method to the true value. It is the measure of the exactness of the analytical 
method developed. Accuracy may often express as percent recovery by the assay of a known 
amount of analyte added. 
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Accuracy may be determined by applying the method to samples or mixtures of excipients to 
which known amount of analyte have been added both above and below the normal levels 
expected in the samples. Accuracy is then calculated from the test results as the percentage of 
the analyte recovered by the assay. Dosage form assays commonly provide accuracy within 
3-5% of the true value. The ICH recommend that accuracy should be assessed using a 
minimum of nine determinations over a minimum of three concentration levels, covering the 
specified range ( i.e. three concentration and three replicated of each concentration). 
Percentage recovery = T - A X 100 / S 
Where T = Total amount of drug estimated 
A= Amount contributed by formulation 
S = Amount of pure drug added. 
2. PRECISION: 
Precision of analytical method is expressed as SD and RSD of series of measurement by 
replicate estimation of drug. Repeatability involves analysis of replicates by the analyst using 
the same equipment and method and conducting the precision study over short period of time 
while reproducibility involves precision study at 
- Different Occasions, 
- Different Laboratories, 
- Different Batch of Reagent, 
- Different Analysts, 
- Different Equipments. 
The RSD values are important for showing degree of variation expected when the 
analytical procedure is repeated several time in a standard situation. (RSD below 1% for bulk 
drugs,  RSD below 2% for assays in finished product). 
 
3. LINEARITY AND RANGE: 
           The linearity of an analytical method is its ability to elicit test results that are directly  
proportional to the analyte concentration in sample within a given range. Linearity usually  
Expressed in terms of the variance around the slope of regression line calculated according to  
an established mathematical relationship from test results obtained by the analysis of samples  
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With varying concentrations of analyte.The working sample concentration and sample tested  
For accuracy should be in the linear range. The claim that the method is linear to be justified  
with additional mention of zero intercept by processing data by linear least square regression  
Declaring the regression co-efficient and b of the linear equation y = ax+ b together with the  
Correlation coefficient of  determination ‘r’. For the method to be linear the ‘r’ value should  
be close to 1. 
4. LIMIT OF DETECTION AND LIMIT OF QUANTITATION:-  
LIMIT OF DETECTION: 
The limit of detection is the parameter of limit tests. It is the lowest level of analyte 
that can be detected, but not necessarily determined in a quantitative fashion, using a specific 
method under the required experimental conditions. The determination of the limit of 
detection of instrumental procedures is carried out by determining the signal-to-noise ratio by 
comparing test results from the samples with known concentration of analyte with those of 
blank samples and establishing the minimum level at which the analyte can be reliably 
detected. A signal-to-noise ratio of 2:1 or 3:1 is generally accepted.  
 
For spectroscopic techniques or other methods that rely upon a calibration curve for 
quantitative measurements, the IUPAC approach employs the standard deviation of the 
intercept (Sa) which may be related to LOD and the slope of the calibration curve, b, by  
 
LOD = 3 Sa / b 
 
LIMIT OF QUANTITATION: 
The limit of quantitation is the lowest concentration of analyte in a sample that may 
be determined with acceptable accuracy and precision when the required procedure is 
applied.  
It is measured by analyzing samples containing known quantities of the analyte and 
determining the lowest level at which acceptable degrees of accuracy and precision are 
attainable where the final assessment is based on an instrumental reading, the magnitude of 
background response by analyzing a number of blank samples and calculating the standard 
deviation of this response. The standard deviation multiplied by a factor (usually 10) provides 
an estimate of the limit of quantitation. In many cases, the limit of quantitation is 
approximately twice the limit of detection.  
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5. SELECTIVITY AND SPECIFICITY: 
        The selectivity of an analytical method is its ability to measure accurately and 
specifically the analyte of interest in the presence of components that may be expected to be 
present in the sample matrix. If any analytical procedure is able to separate and resolve the 
various components of a mixture and detect the analyte qualitatively the method is called 
selective. On the other hand, if the method determines or measures quantitatively the 
component of interest in the sample matrix without separation, it said to be specific.  
       Selectivity may be expressed in terms of the assay results obtained when the procedure is 
applied to the analyte in the presence of expected levels of other components, compared the 
results obtained when the procedure is applied to the analyte in the presence of expected 
levels of other components, compared to the results obtained on the same analyte without 
added substances. When the other components are all known and available, selectivity may 
be determined by comparing the test results obtained on the analyte with and without the 
addition of the potentially interfering materials. When such components are either 
unidentified or unavailable, a measure of selectivity can often be obtained by determining the 
recovery of a standard addition of pure analyte to a material containing a constant level of the 
other components.  
6. ROBUSTNESS AND RUGGEDNESS: 
ROBUSTNESS: 
         The robustness of an analytical method is a measure of its capacity to remain unaffected 
by small but deliberate variation in method parameters and provides an indication of its 
reliability during normal usage. The determination of robustness requires that methods 
characteristics are assessed when one or more operating parameter varied. 
Ruggedness: 
         The ruggedness of an analytical method is the degree of reproducibility of test results 
obtained by the analysis of the same samples under a variety of normal test conditions such as 
different laboratories, different analysts, using operational and environmental conditions that 
may differ but are still within the specified parameters of the assay. The testing of ruggedness 
is normally suggested when the method is to be used in more than one laboratory. 
Ruggedness is normally expressed as the lack of the influence on the test results of 
operational and environmental variables of the analytical method. For the determination of 
ruggedness, the degree of reproducibility of test result is determined as function of the assay 
variable. This reproducibility may be compared to the precision of the assay under normal 
condition to obtain a measure of the ruggedness of the analytical method. 
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7. STABILITY AND SYSTEM SUITABILITY TESTS: 
         Stability of the sample, standard and reagents is required for a reasonable time to 
generate reproducible and reliable results. For example, 24 hour stability is desired for 
solutions and reagents that need to be prepared for each analysis. 
         System suitability test provide the added assurance that on a specific occasion the 
method is giving, accurate and precise results. System suitability test are run every time a 
method is used either before or during analysis. The results of each system suitability test are 
compared with defined acceptance criteria and if they pass, the method is deemed satisfactory 
on that occasion. The nature of the test and the acceptance criteria will be based upon data 
generated during method development optimization and validation experiments. 
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2. REVIEW OF LITERATURE 
¾ Selvadurai Muralidharan et al24; reported a method development and validation for the 
quantitative determination of Dexibuprofen (DI) in pharmaceutical dosage form. The 
method was carried out by reversed phase HPLC technique on a RP-18 column with a 
mobile phase composed of acetonitrile and 0.5 % triethylamine (pH 7.5 adjusted with 
orthophosphoric acid (30:70,v/v)). UV method was performed with the λ max at 222.0 nm. 
Validation parameters such as linearity, precision, accuracy, and specificity were 
determined. 
 
¾ Wan Wen Qing et al25; reported a establish a method for content determination of 
dexibuprofen in the gel preparation by HPLC. Hypersil ODS2 column was used with 
acetonitrile: water (pH 3.0) 58:42 as mobile phase detecting wavelength as 263 nm flow 
rate as 1.0 ml min and temperature as 35ºC. The Dexibuprofen showed a good linear 
correlation with a range of 25.1-251.0 µg/ml, r = 0.9999. The average recovery was 
101.6%. 
 
¾ A. Thenmozhi et al26; reported a method development and validation for Dexibuprofen 
in tablet dosage form by RP-HPLC. The method was carried out on Waters Symmetry 
C18 column in isocratic mode, with mobile phase consisting of Acetonitrile and water in 
the ratio of 55: 45 % (v/v), adjusted to pH 2.5 with orthophosphoric acid. The mobile 
phase was pumped at a rate of 1.5mL/min and detection was carried out at 214nm and 
linearity was found to be in the range of 40 to 160μg/ml. The correlation coefficient was 
found to be 0.9991. Validation of the proposed method has also been done. 
 
¾ P. Balan et al27; reported a method development and validation for the determination of 
Dexibuprofen and Paracetamol in combined tablet dosage form by RP-HPLC. The 
separation was carried out by using a mobile phase consisting of Acetonitrile: water in 
ratio of 50: 50 pH 7.8 adjusted with Triethylamine. The column used was C18, 250 × 4.5 
mm with flow rate of 1.0 ml / min using UV detection at 230 nm. The described method 
was linear over a concentration range of 2-10 μg/ml (r2 =0.999485 and0.999433) and the 
retention times of Dexibuprofen and Paracetamol were found to be 1.763 and 2.463 min 
respectively. The method was validated as per ICH guidelines. 
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¾ Selvadurai Muralidharan et al28; reported a method development and validation for 
analysis of Dexibuprofen in tablet dosage form by HPTLC. The method uses aluminium 
foil HPTLC plates coated with silica gel 60F 254 as stationary phase and hexane: ethyl 
acetate: glacial acetic acid 7.5: 2.5: 0.5 (v/v) as mobile phase. Densitometric analysis of 
dexibuprofen and the internal standard (aceclofenac) was performed in reflectance mode 
at 217 nm. The system was found to give compact bands for Dexibuprofen (RF 0.50). 
Linearity was found to be in the range of 50-300 ng per band (r2 = 0.9902). 
 
 
    
          
 
Departmen
               
 
DEXIBU
¾ Not o
¾ Dexib
dextr
STRUCT
               
CHEMI
         Che
MOLEC
         C13
MOLEC
        206
DESCRI
       A wh
SOLUBI
        Rea
water. 
TABLET
 D
                 
t Of Pharmac
                   
PROFEN:
fficial in an
uprofen is a
orotatory en
URAL FO
  
CAL NAME
mically it is
ULAR FOR
H18O2 
ULAR WE
.28gm/mol 
PTION: 
ite colour p
LITY: 
dily soluble 
 FORMUL
exibuprofen
                
eutical Analy
                   
 
y pharmacop
 Non -Stero
antiomer of 
RMULA29
: 
 (2S)-2-[4-(
MULA: 
IGHT: 
owder.  
in organic s
ATION: 
 300 mg. 
               
sis, RVS Colle
         3. DR
eia 
idal Anti In
ibuprofen.
: 
2-methyl pr
olvent such 
               
ge Of Pharma
UG PROFI
flammatory
opyl) pheny
as ethanol a
                
ceutical Scien
LE 
 and Analge
 
l] propanoic
nd acetone a
           Dru
ces
sic effect. It
 acid(1,2,3)
nd slightly 
g Profile
Page 2
 is the active
 
soluble in   
 
9
 
                                                                                                       Drug Profile 
 
Department Of Pharmaceutical Analysis, RVS College Of Pharmaceutical Sciences Page 30 
 
THERAPEUTIC CATEGORY: 
        Non steroidal anti inflammatory drug. 
PHARMACOKINETICS30-33: 
Dexibuprofen is absorbed primarily from the small intestine. After metabolic transformation 
in the liver (hydroxylation, carboxylation), the pharmacologically inactive metabolites are 
completely excreted, mainly by the kidneys (90%), but also in the bile. The elimination half- 
life is 1.8 - 3.5 hours; the plasma protein binding is about 99 %. Maximum plasma levels are 
reached about 2 hours after oral administration. 
INDICATION : 
¾ Pain and inflammation caused by osteoarthritis. 
¾ Acute symptomatic treatment of pain during menstrual bleeding (primary 
dysmenorrhoea). 
¾ Mild to moderate pain, such as pain in the muscles and joints and toothaches. 
CONTRA INDICATION: 
¾ Hypersensitivity to aspirin or other non-steroidal anti-inflammatory drugs. 
¾ Active or suspected gastrointestinal ulcer . 
¾ Gastrointestinal bleeding or other active bleedings or bleeding disorders. 
¾ Active Crohn's disease or active ulcerative colitis. 
¾ Severe renal dysfunction ,severely impaired hepatic function. 
¾ Haemorrhagic diathesis and other coagulation disorders. 
PRECAUTIONS: 
¾ History of bronchial asthma 
¾ Renal or hepatic disorder 
¾ Bleeding disorders            
¾ Cardio vascular disease. 
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ADVERSE DRUG  REACTION : 
         GI bleeding, heartburn, epigastric pain, dyspepsia,  peptic ulcer,  nausea, vomiting, 
diarrhoea, jaundice, hepatitis, rash, thrombocytopaenia, visual disturbances, depression, 
fatigue, headache, dizziness, vertigo. 
DRUG INTERACTIONS:   
¾ Anticoagulants: The effects of anticoagulants on bleeding time can be potentiated 
by NSAIDs. If concomitant treatment cannot be avoided blood coagulation tests 
(INR, bleeding time) should be performed during the initiation of Dexibuprofen 
treatment and the dosage of the anticoagulant should be adjusted if necessary .  
¾ Methotrexate used at doses of 15 mg/week or more: If NSAIDs and methotrexate 
are given within 24 hours of each other plasma levels of methotrexate may increase, 
via a reduction in its renal clearance thus increasing the potential for methotrexate 
toxicity. Therefore, in patients receiving high-dose treatment with methotrexate, the 
concomitant use of Dexibuprofen is not recommended. 
¾ Lithium: NSAIDs can increase the plasma levels of lithium, by reducing its renal 
clearance. The combination is not recommended. Frequent lithium monitoring 
should be performed. The possibility of reducing the dose of lithium should be 
considered other NSAIDs and salicylates ( acetyl salicylic acid at doses above those 
used for anti-thrombotic treatment, approximately 100 mg/day ) The concomitant 
use with other NSAIDs should be avoided, since simultaneous administration of 
different NSAIDs can increase the risk of gastrointestinal ulceration and 
haemorrhage. 
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                                                            4. AIM AND OBJECTIVE 
¾ Analytical methods by using sophisticated instruments such as HPLC and HPTLC are 
having the vital role in the modern pharmaceutical analysis. Application of these 
instruments for qualitative and quantitative estimation of marketed formulation. 
¾ In this research work we applied two instruments namely HPLC and HPTLC for 
estimation of Dexibuprofen. 
¾ The literature review reveals that one HPTLC method and few HPLC methods in 
Pharmaceutical formulation for the quantification of dexibuprofen. 
¾ The aim of the present work was to develop and validate a simple, fast, and reliable 
RP-HPLC and HPTLC method for the determination of dexibuprofen in tablet dosage 
form. 
¾ Conformation of the applicability of the developed method was validated according to 
the International Conference on Harmonisation to determination of dexibuprofen in 
pharmaceutical dosage forms. 
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                                               5.  PLAN OF WORK 
Development of Validated RP-HPLC and HPTLC Method for Estimation of 
Dexibuprofen in pharmaceutical dosage forms. 
 The plan of the proposed work includes the following steps. 
¾ Selection of the drug. 
¾ Collection of all available information and different analytical procedures related to 
the drug. 
¾ To undertake solubility study for the Dexibuprofen. 
¾ Selection of suitable stationary phase and mobile phases. 
¾ Selection of detection wave length. 
¾ Optimization of chromatographic parameters. 
¾ Preparation of calibration curve. 
¾ Estimation of Dexibuprofen formulation. 
¾ To validate analytical method developed as per the ICH guidelines.  
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6. LIST OF INSTRUMENTS USED 
 
S.NO 
 
INSTRUMENTS 
 
 
1. 
 
SHIMADZU HPLC with UV detector 
 
2. 
 
HYPERSIL BDS C18 column (150 × 4.6mm, 5µ) 
 
3. 
 
CAMAG HPTLC instrument 
 
4. 
 
CAMAG TLC SCANNER 3 
 
5. 
 
CAMAG LINNOMATE V AUTOMAIC SAMPLE 
APPLICATOR 
 
6. 
 
Twin-trough chamber (10 × 10 cm) 
 
7. 
 
Ultra sonicator 
 
8. 
 
Electronic balance (2mg-200gm) (Sartorius) 
 
9. 
 
pH Analyser 
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          LIST OF CHEMICALS AND SOLVENTS 
 
 
S.NO 
 
 
 
CHEMICALS AND SOLVENTS 
 
MANUFACTURER 
 
1. 
 
 
DEXIBUPROFEN working standard 
 
USP standards 
 
2. 
 
 
Acetonitrile (HPLC grade) 
 
Rankem 
 
3. 
 
 
Methanol (HPLC grade) 
 
Fischer scientific 
 
4. 
 
 
Tri ethyl amine 
 
Merck 
 
5. 
 
Toluene  
 
 
Fischer scientific 
 
6. 
 
Chloroform 
 
 
Merck 
 
7. 
 
Ethanol  
 
 
Merck 
 
8. 
 
Acetone  
 
                  
Merck  
 
9. 
 
Ethyl acetate 
 
 
Fischer scientific 
 
10. 
 
 
Glacial acetic acid 
 
Merck 
 
        11. 
 
 
Milli-Q/HPLC water 
 
Merck 
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7. METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF  
DEXIBUPROFEN TABLET DOSAGE FORM BY RP-HPLC 
1. Selection of Column: 
     Experiments with different C18 columns were conducted to achieve best separation. C18 
columns such as  Hypersil BDS C18, was tried. After reviewing the results it was found that 
the peak shape, retention time, resolution, tailing factor, and column efficiency are good with 
Hypersil BDS C18 (150 x4.6mm,5.0µm) column was selected. 
2. SELECTION OF DETECTION WAVELENGTH: 
   The sensitivity of the HPLC method that uses UV detector depends upon the proper 
selection of wavelength. An ideal wavelength which gives good response for the drug to be 
detected is to be selected from the UV spectrum obtained for the drug, 264 nm was selected 
as the wavelength for this method. 
INITIAL CHROMATOGRAPHIC CONDITIONS: 
Stationary phase   :    Hypersil BDS C18, 
                                          (150 × 4.6 mm, 5μm particle size) 
Flow rate           :    1.0 ml/minutes 
Column temperature    :    Ambient 
Wavelength selected  :    264 nm 
3. SELECTION OF MOBILE PHASE: 
  Experiments with different mobile phases were tried in different ratio for the selection of 
mobile phase. So we tried with a  mixture of solvent like  Acetonitrile: water for getting a 
suitable symmetrical peak. After repeated trials this mixture of solvents Acetonitrile: water 
solvent gives a good symmetrical peak. So the above mobile phase was used as a solvent of 
choice for the drug. 
5. EFFECT OF RATIO OF MOBILEPHASE: 
The mobile phase of Acetonitrile : water  in various of  50:50, 55:45, 60:40, were tried and 
the chromatogram were recorded at 264 nm at the ratio of 60:40%v /v was selected as the 
ideal ratio for the estimation of dexibuprofen. But the peak shape was not good so we add the 
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peak modifiers such as 1 ml of glacial acetic acid and 0.2 ml of triethylamine and adjust the 
pH to 5.0± 0.05 to get a sharp symmetrical peak with good retention time. 
6. EFFECT OF FLOW RATE: 
Keeping the mobile phase ratio of Acetonitrile: water (60:40%v/v) the chromatogram was 
recorded at flow rate like 1.0ml/min. In this flow rate the peak was sharp with good 
resolution and it was kept constant for the analysis. 
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SAMPLE PREPARATION:  
            Weigh and transfer 8 tablets into a 200 ml volumetric flask, add 10 ml of water and 
shake for 5 min. Add 100 ml of methanol sonication for 20 minutes with intermediate 
shaking, make up to the volume with methanol and mix well. Filter the solution through a 
0.45µm nylon filter. Dilute 2.0 ml of filtrate to 250 ml volumetric flask and make up to 
volume with diluents. Chromatogram of sample solution is as shown in Fig No: 7 
                      
                    Fig. No: 7 Chromatogram showing peaks of sample solution of Dexibuprofen 
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EVALUATION OF SYSTEM SUITABILITY: 
 The relative standard deviation for the area of five replicate injections of 
Dexibuprofen standard solution-2 should be less than 2.0. 
 Tailing factor for Dexibuprofen peak in the first injection of standard solution-2 
should be less than 2.0. 
 Theoretical plates for Dexibuprofen peak in the first injection of standard solution-2 
should be more than 2000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                      Experimental Details 
 
Department Of Pharmaceutical Analysis, RVS College Of Pharmaceutical Sciences  Page 45 
 
METHOD VALIDATION: 
             Validation is the process of evaluating products or analytical methods. It includes 
testing but it is more for instance, the checking the documentation for completeness and 
correctness. 
             Validation is defined as documented evidence that a system performance as expected. 
OBJECTIVE: 
The objective of this validation study is to demonstrate that the proposed method is suitable 
for its intended use. 
This study covers the following parameters, 
1. Precision 
i. System precision 
ii. Method precision 
iii. Intermediate precision 
2. Specificity 
3. Forced degradation 
4. Linearity 
5. Accuracy  
6. Solution stability 
7. Filter interference study 
8. Robustness 
 SYSTEM SUITABILITY TESTING: 
      The purpose of the system suitability test is to ensure that the complete testing system 
(including instrument, reagents, columns, analysts) is suitable for the intended application. 
System suitability tests are an integral part of liquid chromatographic methods. They are used 
to verify that the resolution and reproducibility of the chromatographic system are adequate 
for the analysis to be done. 
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EVALUATION OF SYSTEM SUITABILITY 
1. The relative standard deviation for the area of five replicate injections of dexibuprofen 
standard solution should be less than 2.0 
2. Tailing factor dexibuprofen peak in the first injection of standard solution should be 
less than 2.0 
3. Theoretical plates for dexibuprofen peak in the first injection of standard solution 
should be more than 2000 and the results are tabulated and are as shown in Table No 
1. PRECISION: 
         The precision of an analytical procedure expresses the closeness of agreement between 
a series of measurements obtained from multiple sampling of the same homogeneous sample 
under the prescribed conditions. Precision may be considered at three levels: Repeatability, 
Intermediate precision and Reproducibility. 
PROCEDURE: 
A) SYSTEM PRECISION: 
Preparation of standard solution (100µg/ml): 
      Weigh accurately and transfer about 50.0 mg of dexibuprofen standard into a 50.0 ml 
volumetric flask, add 30 ml of methanol sonication  to dissolve the content and make up to 
the volume with methanol (stock solution). 
     Dilute 5.0 ml of the above solution to 50.0 ml with diluent and mix well. Inject 10µl of the 
blank solution and the standard solution of 100µg/ml for five times and calculate the %RSD for 
the area of five replicate injections. The chromatograms are as shown in Fig No: 8 and the results 
are tabulated in table – 2.  
ACCEPTANCE CRITERIA: 
       Percentage relative standard deviation (%RSD) for peak areas of dexibuprofen is not 
more than 2.0. 
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              Fig No: 8 Chromatogram showing System Precision of Dexibuprofen 
 
           
B) METHOD PRECISION: 
Preparation of sample solution: 
         Weigh and transfer 8 tablets in to a 200.0 ml volumetric flask, add 10 ml of water and 
shake for 5 minutes. Add 100 ml of methanol, sonication for 20 minutes with intermediate 
shaking and make up to the volume with methanol. Mix well and filter the solution through a 
0.45µm nylon filter. Dilute 2.0 ml of filtrate to 250.0 ml with diluent. 
         Inject 10µl of the blank solution and six replicate injections of sample solution for six times 
and calculate the %RSD for the area of six replicate injections. The chromatograms are as shown 
in Fig No: 9 and the results are tabulated in table – 3. 
ACCEPTANCE CRITERIA: 
  Percentage relative standard deviation (%RSD) for percentage of assay is not more than 2.0. 
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               Fig No: 9 Chromatogram showing Method Precision of Dexibuprofen 
 
 
C) INTERMEDIATE PRECISION (RUGGEDNESS): 
         Ruggedness of the method was verified by analysing the six samples of 300 mg tablets 
of same batch which was used for method precision as per testing procedure. This study was 
performed by different analyst using different instrument and different column on different 
day. Calculated the percentage assay and percentage relative standard deviation (%RSD) for 
six assay results. Calculated overall percentage relative standard deviation (%RSD) for 
ruggedness and method precision results. The chromatograms are as shown in Fig No: 10.    
The results are tabulated in table – 4. 
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ACCEPTANCE CRITERIA: 
 Percentage relative standard deviation (%RSD) for assay is not more than 2.0. 
          Fig No: 10 Chromatogram showing Intermediate Precision of Dexibuprofen 
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2. SPECIFICITY: 
         Blank, placebo, standard, sample solution (unspiked) and sample solution spiked with 
known impurities at 1% level were injected into the HPLC system. There was no interference 
from the blank and placebo at the retention time of dexibuprofen peak.  
        Peak purity data reveals that dexibuprofen peak was homogenous and there were no co-
eluting peaks at the retention time of dexibuprofen peak.  
          Calculated the percentage difference between the mean assay of unspiked and spiked 
sample with respect to unspiked sample. The results are tabulated in table – 5a. The peak 
purity data of dexibuprofen peak from standard, sample (unspiked) and spiked sample are 
summarized in table – 5b.  The chromatograms are as shown in Fig No: 11 and 12. 
ACCEPTANCE CRITERIA: 
i. No peaks elutes at the retention time of dexibuprofen in blank and placebo. 
ii. The percentage difference between the assay values of spiked and unspiked sample is 
not more than ± 2.0 with respect to unspiked sample. 
iii. Peak purity passes. 
                    Fig No: 11 Chromatogram showing specificity of Dexibuprofen 
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         Fig No: 12 Chromatogram showing specificity of Dexibuprofen 
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3. FORCED DEGRADATION: 
    Forced degradation study was carried out by treating the sample under the following 
conditions. 
a) Degradation By Hydrochloric Acid (Acid Treated Sample): 
    Sample was treated with 10 ml of 5N Hydrochloric acid and kept on bench top for 12 
hours. Treated sample solution was analysed as per the testing procedure. 
b) Degradation By Sodium Hydroxide (Base Treated Sample): 
     Sample was treated with 10 ml of 5N sodium hydroxide and kept on bench top for 12 
hours. Treated sample solution was analysed as per the testing procedure. 
c) Degradation By Hydrogen Peroxide (Peroxide Treated Sample): 
    Sample was treated with 10 ml of 30% solution of hydrogen peroxide and kept on bench 
top for 12 hours. Treated sample solution was analysed as per the testing procedure. 
d) Degradation By Thermal (Heat Treated Sample): 
     Sample was kept in an oven at 105ºc for about 24 hours. Treated sample was analysed as 
per the testing procedure. 
e) Degradation By Photo Light [Controlled Condition (Wrapped In Aluminium Foil)]: 
     Sample was exposed to light of 1.2 million lux hours in protected condition. Treated 
sample was analysed as per the testing procedure. 
f) Degradation By Photo Light [Uncontrolled Condition]: 
   Sample was exposed to light of 1.2 million lux hours. Treated sample was analysed as per 
the testing procedure. 
The results of forced degradation studies are summarized in table – 6. 
ACCEPTANCE CRITERIA: 
i. Peak purity for main peak passes. 
ii. Degradation is not more than 30% in each condition. 
                                                                                      Experimental Details 
 
Department Of Pharmaceutical Analysis, RVS College Of Pharmaceutical Sciences  Page 53 
 
4. LINEARITY & RANGE: 
     The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the sample. 
      The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for which it 
has been demonstrated that the analytical procedure has a suitable level of precision, accuracy 
and linearity. 
PROCEDURE: 
Preparation of standard stock solution: 
      Weigh accurately and transfer about 50.0 mg of dexibuprofen standard into a 50.0 ml 
volumetric flask, add 30 ml of methanol sonication to dissolve the content and make up to the 
volume with methanol.  
Preparation of (20, 40, 60, 80, and 100 µg/ml) sample solutions: 
From the above stock solution pipette out 1.0, 2.0, 3.0, 4.0, 5.0 ml respectively into individual 
50ml of volumetric flasks and dilute up to the mark with diluent to prepare 20, 40, 60, 80, 
100 µg/ml of sample solutions respectively.       
  Inject 10µl of blank solution and each linearity level standard solutions into the 
chromatographic system and measure the peak area.  
            The linearity of dexibuprofen was performed in the range of 20µg/ml to 100µg/ml 
(20% to 100% of working concentration). A graph was plotted with concentration (µg/ml) on 
x- axis and peak area on y- axis. Slope, y- intercept, correlation coefficient (r- value) were 
determined (Fig No: 14). 
The chromatograms are as shown in Fig No: 13. The results are tabulated in table – 7. 
ACCEPTANCE CRITERIA: 
The correlation coefficient (r) value is not less than 0.99. 
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                       Fig No: 13 Chromatogram showing Linearity of Dexibuprofen 
 
                      
                                       Fig: 14 Calibration curve for Dexibuprofen 
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5. ACCURACY: 
        The accuracy of an analytical method may be defined as the closeness of the test results 
obtained by the method to the true value. It is the measure of the exactness of the analytical 
method developed. Accuracy may often express as percent recovery by the assay of a known 
amount of analyte added. 
        The accuracy was demonstrated by preparing recovery sample. Known amount of 
dexibuprofen spiked with placebo at about 80%, 100% and 120% of working concentration in 
triplicate and analysed. Prepared each level in the triplicates and the average value taken to 
calculate the recovery. The percentage recovery was calculated from the amount found and 
actual amount added. 
The chromatograms are as shown in Fig No: 15-16.1. The results are tabulated in table – 8. 
ACCEPTANCE CRITERIA: 
Percentage recovery at each level is in between 98.0 to 102.0 
Percentage relative standard deviation (%RSD) is not more than 2.0 at each level. 
 
 
Fig No: 15 Chromatogram showing  80 %Accuracy  of Dexibuprofen 
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Fig No: 16.1 Chromatogram showing 100% Acurracy of Dexibuprofen 
 
 
 
Fig No: 16.2 Chromatogram showing 120% Acurracy of Dexibuprofen 
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6. SOLUTION STABILITY: 
    Stability of analytical solution was verified by analysing the standard solution and sample 
solution of 300 mg tablets initially and also at different time intervals (4, 8, 12,16,20,24 hrs.) 
by storing in sample compartment of HPLC instrument at  25ºC (ambient). Calculated the 
cumulative percentage relative standard deviation (%RSD) for peak areas of dexibuprofen in 
standard and sample. The chromatograms are as shown in Fig No: 17. The results are tabulated 
in table – 9. 
ACCEPTANCE CRITERIA: 
      Cumulative percentage relative standard deviation (% RSD) is not more than 2.0 for 
peaks areas of standard and sample. 
               Fig No: 17 Chromatogram showing Solution stability of Dexibuprofen 
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7. FILTER INTERFERENCE STUDY: 
    Filter interference study was performed on sample solution of 300 mg tablets. Prepared 
sample as per testing procedure filtered the solution through 0.45µ nylon filter, analysed the 
sample and the result compared with centrifuged sample result. 
The results are tabulated in table – 10. 
ACCEPTANCE CRITERIA: 
   The percentage difference between centrifuged and filtered sample results is not more than 
± 2.0 with respect to centrifuged sample results. 
8. ROBUSTNESS: 
     The evaluation of robustness should be considered during the development phase and 
depends on the type of procedure under study. It should show the reliability of an analysis 
with respect to deliberate variations in method parameters. 
   Robustness of the method verified by deliberately varying the following instrumental 
conditions. 
a) By changing the flow rate by ± 0.1ml (0.9ml, and 1.1ml) variation to normal flow rate 
of 1.0 ml. 
b) By changing the wavelength by ± 2 nm. (218nm and 220nm) variation from normal 
wavelength of 220nm. 
c) By changing the mobile phase pH by ± 0.2 units (4.8 and 5.2) variation from normal 
mobile phase pH 5.0. 
Preparation of standard solution (100µg/ml): 
    Weigh accurately and transfer about 50.0 mg of dexibuprofen standard into a 50.0 ml 
volumetric flask, add 30 ml of methanol sonication to dissolve the content and make up to the 
volume with methanol. Dilute 5.0 ml of the above solution to 50.0 ml with diluent and mix 
well. 
       Inject 10µl of the blank solution and the standard solution of 100 µg/ml for triplicate and 
analysed using varied flow rates (0.9ml, and 1.1 ml), wavelength (218nm and 222nm), 
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mobile phase pH (4.8 and 5.2) and calculate the %RSD for the area of triplicate injections and 
the results are tabulated in table – 11. 
ACCEPTANCE CRITERIA: 
     Overall percentage relative standard deviation (%RSD) for assay of each change condition 
and the results is not more than ± 2.0. 
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METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF 
DEXIBUPROFEN IN PHARMACEUTICAL DOSAGE FORM BY HPTLC 
METHOD DEVELOPMENT: 
1. Selection of Mobile Phase: 
 The selection of mobile phase was done by trial and error method in which several 
mobile phases were tried. The best mobile phase was selected based on the Rf value of the 
drugs. The mobile phase tried were listed below, 
1. Chloroform : Ethanol  (8: 2% v/v) 
2. Toluene: Ethyl Acetate: Methanol: Acetic Acid (7: 1.5: 1:0.5%v/v/v/v) 
3. Acetone: Benzene: Ethyl acetate: Glacial acetic acid(6: 1:  2: 1%v/v/v/v) 
4. Toluene: Ethyl acetate: Glacial acetic acid (6 :3 :1% v/v/v) 
2. Fixed Mobile Phase:  
 For Dexibuprofen Toluene: Ethyl acetate: Glacial acetic acid (6: 3: 1% v/v/v)  was 
selected as mobile Phase. 
3. Activation of Pre-Coated Plates: 
 Activated by placing in oven at110-120ºc for 30 minutes after sample spotting 
 4. Sample Preparation: 
  Preparation of Standard Stock Solution: 
            The standard stock solutions of 1000 μg/ml of Dexibuprofen were prepared by 
weighing 100mg of Dexibuprofen dissolved with methanol in 100 ml volumetric flask and 
made up to the volume. 
  5. Application of Sample: 
              Generally 1.0-5.0µg/spot is most satisfactory for HPTLC application of the sample 
& standard as a band gives better separation, equal Rf values, and less spot broadening .The 
sample is applied a series of 1µg, 2µg, 3µg, 4µg & 5µg/spot Standard of Dexibuprofen 
solution were loaded as 4mm band length in the 6 x 10 Silica gel 60F254 TLC plate using 
100µl Hamilton syringe and CAMAG-LINOMAT-5 instrument. 
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6.  Spot Development : 
 The Sample and standards loaded plate was kept in Twin trough chamber 10 x 10cm 
with respective mobile phase up to 15min for Chamber saturation. After completion of 
chamber saturation, the plate was kept in mobile phase for development up to 90mm. 
7. Photo-Documentation: 
The developed plate was dried by hot-air to evaporate solvents from the plate and the 
plate was kept in Photo-documentation chamber.  The images of developed plate were 
captured at white light, UV 254nm and UV 366nm using CAMAG-REPROSTAR-3 
instrument. 
8. Scanning: 
The developed plate was scanned in UV 254nm wavelength for Dexibuprofen using 
CAMAG-TLC SCANNER-3 instrument.  The Baseline display, Peak densitogram & Peak 
table of each track were obtained.  The Dexibuprofen content present in the loaded sample 
was evaluated by Peak assignment with 5 level Dexibuprofen standards.   
9. Spectrum scanning:   
 The assigned peaks of standards and sample were scanned in spectrum of UV region 
(200nm-400nm) and found the λmax value of Dexibuprofen. 
10. Linearity: 
  Aliquots of 1-5 µg/spot of standard solution of Dexibuprofen is applied on the 
plate  with the help of micro litre syringe using an automatic sample applicator. The plates 
were developed, dried and scanned densitometrically at 254 nm. The drug peak-area was 
calculated for each concentration level and a graph was plotted of drug concentration against 
the peak area and shown in (Fig: 18.6 – 18.12 Table: 14). Calibration parameters are given in 
Table: 15.                                                         
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HPTLC CHROMATOGRAMS FOR DEXIBUPROFEN: 
Fig: 18 Daylight before mobile phase run          Fig: 18.1 UV 366nm before mobile phase run 
 
                       
                  Fig: 18.2 UV 254nm before mobile phase run 
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                               Fig: 18.6 DEXIBUPROFEN DENSITOGRAM – 1 µg 
 
 
                              Fig: 18.7 DEXIBUPROFEN DENSITOGRAM – 2 µg 
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                               Fig: 18.8 DEXIBUPROFEN DENSITOGRAM – 3 µg 
 
 
                               Fig: 18.9 DEXIBUPROFEN DENSITOGRAM – 4 µg 
 
 
                                                                                      Experimental Details 
 
Department Of Pharmaceutical Analysis, RVS College Of Pharmaceutical Sciences  Page 66 
 
                                 Fig: 18.10 DEXIBUPROFEN DENSITOGRAM – 5 µg 
   
                             
                          Fig: 18.12 Calibration Curve of Dexibuprofen at 254 nm 
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ANALYSIS OF FORMULATION: 
Preparation of Sample Solution: 
 Twenty tablets were powdered and weighed equivalent to 100 mg of Dexibuprofen 
which is transferred in to a100ml volumetric flask and extracted with methanol the extract 
was filtered through Whatman filter paper No.41 and residue washed with methanol and 
made up to 100ml with methanol. Aliquot of 3μg solution of tablet formulation were applied 
and plate was developed with mobile phase.  
Assay: 
 The sample solutions were spotted along with the standard to check the specificity. 
Spotted 3μg of sample solution allowed to develop in appropriate mobile phase and detect the 
spots as described earlier. From the peak area recorded the amount of the drug in the 
formulation was determined (Table: 13). 
   ANALYSIS OF FORMULATION: 
                 Fig: 18.11 Scanning Peak densitogram of DEXIBUPROFEN sample 
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  METHOD VALIDATION:      
 1. Linearity: 
              Aliquots of 1-5 µg/spot of standard solution of Dexibuprofen is applied on the plate 
with the help of micro liter syringe using an automatic sample applicator. The plates were 
developed, dried and scanned densitometrically at 254 nm. The drug peak-area was 
calculated for each concentration level and a graph was plotted of drug concentration against 
the peak area and shown in Table: 14, Fig.18.12. Calibration parameters are given in            
Table: 15.                                                                                                          
                               Fig: 18.12 Calibration Curve of Dexibuprofen at 254 nm 
                 
 
2. Accuracy:  
              Accuracy of the developed method was confirmed by doing a recovery study as per 
ICH guidelines at three different concentration levels (80%, 100% and 120%) by replicate 
analysis (n=3). Standard drug solutions were added to a preanalyzed sample solution, and 
then percentage of drug content was calculated. The results of the accuracy study are reported 
in Table 16. From the recovery study, it was clear that the method is very accurate for 
quantitative estimation of Dexibuprofen in tablet dosage form because all the statistical 
results were within the acceptance range (i.e., % RSD <2.0). 
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3. Precision: 
        The precision of the method (system reproducibility) was assessed by spotting 3µl of 
drug solution six times on a TLC plate, followed by development of plate and recording the 
peak area for 6 spots. The % RSD for peak area values of Dexibuprofen was found to be 
0.86%. The results were shown in Table-17.  
             The method reproducibility (intra-day precision) was determined by analyzing 
standard solution in the concentration range of 1 µg/spot to 5 µg/spot of drug for 3 times on 
the same day and inter-day precision was determined by analysing corresponding standards 
daily for 3 day over a period of one week. The intra-day and inter-day coefficients of 
variation (%RSD) are in range of 0.13 to 1.6 and 0.14 to 0.40, respectively. The results were 
shown in Table- 17a, 17b. 
                                                                                   Result And Discussion 
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8. RESULT AND DISCUSSION 
In the present work a new method development and validation was carried out for the 
estimation of dexibuprofen tablets in pharmaceutical dosage form by RP-HPLC and HPTLC 
method. 
METHOD DEVELOPMENT AND VALIDATION OF DEXIBUPROFEN TABLETS 
ASSAY BY RP-HPLC: 
METHOD DEVELOPMENT: 
¾ To develop an effective method for the analysis of the dexibuprofen in 
pharmaceutical formulations. Preliminary tests were performed in order to select 
adequate and optimum conditions.   
¾ Parameters such as detection of wavelength, ideal mobile phase and their 
proportions, optimum pH and concentration of standard solution were studied. 
¾ Preliminary studies involved experiments with different C18 columns were conducted 
to achieve best separation. C18 columns such as  Hypersil BDS C18  was tried.   
¾ After reviewing the results it was found that the peak shape, retention time, 
resolution, tailing factor, and column efficiency are good with Hypersil BDS C18 
(150 x4.6mm,5.0µm) column was selected. 
¾ During the stage of method development mixture of mobile phases was tried and the 
mobile phase comprising of acetonitrile: water (60: 40 % v/v) with 1 ml of glacial 
acetic acid and 0.2 ml of triethylamine. Adjust the pH to 5.0 ± 0.05 using 
triethylamine or glacial acetic acid by isocratic elution, Dexibuprofen showed a 
retention time of 4.5 ± 0.3 minutes respectively, with the flow rate of 1.0ml/ min and 
a detection wave length of 264nm with injection volume of 10µl at ambient 
temperature. Therefore, the tailing factor, resolution and peak shape was found to be 
good in the finally reported conditions for the dexibuprofen. The chromatograms of 
trial methods were as shown in Fig.No:2-4 and optimized method were as shown in 
Fig. No: 5-7. The assay results were as shown in Table No: 1. 
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RESULTS OF TRIAL- 1: 
In this trial-1 Dexibuprofen shows good absorbance at 264 nm, so it was selected as 
wavelength of detection. The mobile phase consisting of Acetonitrile: water (50: 50%v/v), 
Column used as Hypersil BDS column (150 × 4.6mm, 5µ), Flow rate 1.0 ml were tried to 
achieve the separation. But it was found that multiple peaks are present in the  chromatogram.  
RESULTS OF TRIAL – 2: 
Next trial was made with changing the mobile phase ratio consisting                   
Acetonitrile: water (55: 45% v/v), column used as Hypersil BDS column (150 × 4.6mm, 5µ), 
Flow rate 1.0 ml in this trial chromatogram shows peak tailing was observed and the peak 
shape and height was not found to be good. 
RESULTS OF TRIAL – 3: 
     The mobile phase of Acetonitrile: water was tried and the chromatogram was recorded at 
264 nm at the ratio of (60:40% v/v) was selected as the ideal ratio for the estimation of 
dexibuprofen and add 0.1 ml of triethylamine. But the chromatogram shows the retention 
time of the peak was observed at 4.8 min and a small humb was present.  
RESULTS OF  FINAL OPTIMIZED METHOD: 
    Keeping the mobile phase ratio of Acetonitrile: water (60:40%v/v) and add the peak 
modifiers such as 1 ml of glacial acetic acid and 0.2 ml of triethylamine and adjust the pH to 
5.0± 0.05. The chromatogram was recorded to get a sharp symmetrical peak with good 
retention time.                  
 
Table No: 1 Table showing Assay Results of Dexibuprofen tablets 
Name Retention   
time (min) 
Area USP 
Tailing 
USP Plate 
Count 
Amount of 
drug (mg) 
Amount of drug 
(%) 
 
Dexibuprofen 
 
 
4.456 
 
2213622 
 
1.2 
 
485 
 
298.3 
 
99.4 
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METHOD VALIDATION: 
After method development, the validation of the current method has been performed. The 
objective of method validation is to demonstrate that the method is suitable for its intended 
purpose as it is stated in ICH guidelines. 
The method was validated for linearity, accuracy, precision, range, specificity, solution 
stability, filter interference study, and force degradation. 
¾ System suitability tests were carried out by five replicate injections, the peak area and 
retention time was calculated. The %RSD of peak area and the retention time was 
within the limit of ±2%. This indicates that the method was system suitable. 
¾ The linearity of Dexibuprofen were determined and the linearity based on the area 
observed in the range of 20-100 μg /ml. The regression co-efficient  value was found 
to be 0.9999.  
¾ The accuracy was studied by the recovery studies. Known amount of dexibuprofen 
spiked with placebo at about 80%, 100% and 120% of working concentration in 
triplicate and analysed as per testing procedure. The percentage recovery was 
Dexibuprofen was found to be in the range of 99.80 – 100.27 %.  
4.     RESULTS 
4.1   PRECISION: 
4.1.1 SYSTEM PRECISION: 
         Five replicate injections of standard solution were injected. The mean and percentage                        
relative standard deviation (% RSD) for peak areas of dexibuprofen were calculated. The 
results are tabulated in table-2. 
     Percentage relative standard deviation (%RSD) for peak areas of dexibuprofen is not 
more than 2.0. 
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                                                     SYSTEM PRECISION 
                                                              TABLE -2 
 
INJECTION NO  
(std conc: 100µg/ml) 
 
PEAK AREA 
1. 2264976 
2. 2271195 
3. 2273532 
4. 2283832 
5. 2267417 
Mean 2272190 
Percentage relative standard 
deviation (%RSD) 
 
0.3 
 
CONCLUSION: 
     Percentage relative standard deviation (%RSD) value indicates an acceptable level of 
precision of the analytical system for the determination of assay of dexibuprofen tablets. 
4.1.2 METHOD PRECISION 
         Six samples of 300 mg tablets prepared and analysed as per testing procedure. The 
percentage of assay in six samples and percentage relative standard deviation (%RSD) were 
calculated. The results are tabulated in table - 3. 
       Percentage relative standard deviation (%RSD) for percentage of assay is not more 
than 2.0. 
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METHOD PRECISION 
TABLE – 3 
 
 
CONCLUSION: 
    Percentage relative standard deviation (%RSD) value indicates an acceptable level of 
precision of the analytical method for the determination of assay of dexibuprofen tablets. 
4.1.3 INTERMEDIATE PRECISION (RUGGEDNESS): 
    Ruggedness of the method was verified by analysing the six samples of 300 mg tablets of     
same batch which was used for method precision as per testing procedure. This study was 
performed by different analyst using different instrument and different column on different 
day. Calculated the Percentage assay and percentage relative standard deviation (%RSD) for 
six assay results. The results are tabulated in table – 4. 
    Percentage relative standard deviation (%RSD) for assay is not more than 2.0 
     
 
 
 
SAMPLE NO  
( 96µg/ml) 
 
PERCENTAGE ASSAY 
Sample 1 101.8 
Sample 2 120.1 
Sample 3 99.6 
Sample 4 98.1 
Sample 5 101.6 
Sample 6 103.2 
Average 101.1 
Percentage relative standard 
deviation (%RSD) 
 
1.8 
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                                        INTERMEDIATE PRECISION 
                                                            TABLE - 4 
 
SAMPLE NO 
(96µg/ml) 
 
PERCENTAGE OF ASSAY 
 
ANALYST – 1 
 
ANALYST – 2 
Sample 1 101.8 101.3 
Sample 2 120.1 100.6 
Sample 3 99.6 100.1 
Sample 4 98.1 101.1 
Sample 5 101.6 101.1 
Sample 6 103.2 102.2 
Average 101.1 101.1 
Percentage relative standard 
deviation (%RSD) 
 
1.8 
 
0.7 
 
CONCLUSION: 
    Percentage relative standard deviation (%RSD) value indicates an acceptable level of 
ruggedness of the analytical method for the determination of assay of dexibuprofen tablets. 
3.2 SPECIFICITY: 
      Blank, placebo, standard , sample solution (unspiked) and sample solution spiked with 
known impurities at 1% level were injected into the HPLC system. There was no interference 
from the blank and placebo at the retention time of dexibuprofen peak. Peak purity data 
reveals that dexibuprofen peak was homogenous and there were no co-eluting peaks at the 
retention time of dexibuprofen peak. Calculated the percentage difference between the mean 
assay of unspiked and spiked sample with respect to unspiked sample. The results are 
tabulated in table – 5a. The peak purity data of dexibuprofen peak from standard , sample 
(unspiked) and spiked sample are summarized in table – 5b.  
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ACCEPTANCE CRITERIA: 
i. No peaks elutes at the retention time of dexibuprofen in blank and placebo. 
ii. The percentage difference between the assay values of spiked and unspiked sample is 
not more than ± 2.0 with respect to unspiked sample. 
iii. Peak purity passes. 
                                         
                                 SPECIFICITY OF DEXIBUPROFEN 
TABLE – 5 A 
 
Mean % Assay Of Sample 
(Unspiked) 
 
Mean % Assay Of Spiked 
Sample 
 
% Difference 
 
98.5 
 
100.4 
 
1.5 
 
                                                                
                             TABLE – 5 B: PEAK PURITY OF DEXIBUPROFEN 
Peak Name 
 
Sample Type Purity 
Angle 
Purity 
Threshold 
Purity Flag 
 
 
Dexibuprofen 
 
Standard 
 
0.289 
 
0.516 
 
No 
 
Sample (unspiked) 
 
0.286 
 
0.524 
 
No 
 
Spiked sample 
 
0.425 
 
0.495 
 
No 
 
CONCLUSION: 
    The method is specific for the determination of assay of dexibuprofen tablets. 
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3.3 FORCED DEGRADATION: 
      Forced degradation study was carried out by treating the sample under the following 
conditions. 
a) Degradation By Hydrochloric Acid (Acid Treated Sample): 
    Sample was treated with 10 ml of 5N Hydrochloric acid and kept on bench top for 12 
hours. Treated sample solution was analysed as per the testing procedure. 
b) Degradation By Sodium Hydroxide (Base Treated Sample): 
    Sample was treated with 10 ml of 5N sodium hydroxide and kept on bench top for 12 
hours. Treated sample solution was analysed as per the testing procedure. 
c) Degradation By Hydrogen Peroxide (Peroxide Treated Sample): 
    Sample was treated with 10 ml of 30% solution of hydrogen peroxide and kept on bench 
top for 12 hours. Treated sample solution was analysed as per the testing procedure. 
d) Degradation By Thermal (Heat Treated Sample): 
    Sample was kept in an oven at 105ºc for about 24 hours. Treated sample was analysed as 
per the testing procedure. 
e) Degradation By Photo Light [Controlled Condition (Wrapped In Aluminium Foil)]: 
    Sample was exposed to light of 1.2 million lux hours in protected condition. Treated 
sample was analysed as per the testing procedure. 
F) Degradation By Photo Light [Uncontrolled Condition]: 
   Sample was exposed to light of 1.2 million lux hours. Treated sample was analysed as per 
the testing procedure. The results of forced degradation studies are summarized in table – 6. 
Acceptance criteria 
i. Peak purity for main peak passes. 
ii. Degradation is not more than 30% in each condition. 
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 Forced Degradation 
            Table – 6 
 
SL. No 
 
Condition 
 
% 
Assay 
 
% 
Degradation
Peak Purity Of Dexibuprofen 
Purity 
Angle 
Purity 
Threshold 
Purity 
Flag 
 
1. 
 
Untreated Sample 
 
100.8 
 
 
- 
 
0.293 
 
0.519 
 
No 
 
2. 
 
Acid Stressed 
Sample 
 
89.9 
 
10.9 
 
0.314 
 
0.539 
 
No 
 
3. 
 
Alkali Stressed 
Sample 
 
98.7 
 
2.1 
 
0.333 
 
0.561 
 
No 
 
4. 
 
Peroxide Stressed 
Sample 
 
99.0 
 
1.8 
 
0.319 
 
0.536 
 
No 
 
5. 
 
Thermal Stressed 
Sample 
 
79.8 
 
21.0 
 
0.380 
 
0.610 
 
No 
 
6. 
 
Photo Light Stressed 
Sample Controlled 
Condition 
 
99.8 
 
1.0 
 
0.331 
 
0.567 
 
No 
 
7. 
 
Photo Light Stressed 
Sample Uncontrolled 
Condition 
 
98.4 
 
2.4 
 
0.286 
 
0.516 
 
No 
 
Conclusion: 
   The method is stability indicating for determination of assay of dexibuprofen tablets. 
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3.4 Linearity 
      The linearity of dexibuprofen was performed in the range of 20 µg/ml to 100 µg/ml (20% 
to 100% of working concentration). A graph was plotted with concentration ( in µg/ml) on x- 
axis and peak area on y- axis. Slope, y- intercept, correlation coefficient (r- value) were 
determined. 
The results are tabulated in table – 7. 
Acceptance criteria: 
  The correlation coefficient (r) value is not less than 0.99. 
                                                               LINEARITY 
TABLE – 7 
  
Level 
 
 
Concentration In µg/ml 
 
Peak Area 
20% 20 477056 
40% 40 922708 
60% 60 1416756 
80% 80 1903940 
100% 100 2339886 
Slope 23534 
y – intercept                                             0.7619 
Correlation coefficient 0.9999 
                                      
Conclusion: 
     The detector response is directly proportional to concentration ranging 20µg/ml to 
100µg/ml (20% to 100% of working concentration). 
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3.5 Accuracy (Recovery): 
      The accuracy of an analytical method may be defined as the closeness of the test results 
obtained by the method to the true value. It is the measure of the exactness of the analytical 
method developed. Accuracy may often express as present recovery by the assay of a known 
amount of analyte added. 
     The accuracy was demonstrated by preparing recovery sample. Known amount of 
dexibuprofen spiked with placebo at about 80%, 100% and 120% of working concentration in 
triplicate and analysed. Prepared each level in the triplicates and the average value taken to 
calculate the recovery. The percentage recovery was calculated from the amount found and 
actual amount added. 
The results are tabulated in table – 8. 
Acceptance criteria: 
  Percentage recovery at each level is in between 98.0 and 102.0. 
  Percentage relative standard deviation (%RSD) is not more than 2.0 at each level. 
                                                     Accuracy (Recovery) 
                                                              Table – 8 
 
Level 
Actual 
Amount 
Added  
(in mg) 
Amount 
Found  
(in mg) 
 
% Recovery 
 
Mean 
(n =3) 
 
% RSD 
 
Level – 1 
(80%) 
240.43 240.58 100.06  
100.27 
 
 
0.4 238.72 240.92 100.09 
239.56 241.15 100.66 
 
Level – 2 
(100%) 
298.84 300.15 100.43  
99.99 
 
0.3 300.03 299.87 99.94 
301.25 300.12 99.62 
 
Level – 3 
(120%) 
361.36 360.22 99.68  
      99.80 
 
0.1 360.05 359.13 99.74 
360.98 361.01 100.00 
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CONCLUSION: 
    The analytical method meets the pre-established acceptance criteria for accuracy study as 
per protocol. Hence the method is accurate for the determination of assay of Dexibuprofen 
tablets. 
3.6 RANGE: 
      Range inferred from the data of linearity, accuracy and precision experiments. 
3.7 SOLUTION STABILITY: 
     Stability of analytical solution was verified by analysing the standard solution and sample 
solution of 300 mg tablets initially and also at different time intervals as mentioned below by 
storing in sample compartment of HPLC instrument at25ºC (ambient). Calculated the 
percentage relative standard deviation (%RSD) for peak areas of dexibuprofen in standard 
and sample. The results are tabulated in table – 9. 
ACCEPTANCE CRITERIA: 
     Percentage relative standard deviation (% RSD) is not more than 2.0 for peaks areas of 
standard and sample. 
                                                      SOLUTION STABILITY 
Table – 9 
 
Time In hrs. 
Standard Solution Sample Solution 
Peak Area      %    RSD Peak Area  % RSD 
Initial 2272190 - 2223022 - 
4 2271777 0.01 2217590 0.2 
8 2282898 0.3 2218966 0.1 
12 2248931 0.6 2195335 0.6 
16 2285267 0.6 2183930 0.8 
20 2279895 0.6 2222586 0.7 
24 2278672 0.5 2232002 0.8 
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CONCLUSION: 
     As the  percentage relative standard deviation (% RSD) for standard and sample solution 
were within the acceptance criteria, hence it was concluded that standard solution and filtered 
sample solutions are stable up to 24 hours at 25ºC(ambient). 
3.8 FILTER INTERFERENCE STUDY: 
      Filter interference study was performed on sample solution of 300 mg tablets. Prepared 
sample as per testing procedure filtered the solution through 0.45µ nylon filter, analysed the 
sample and the result compared with centrifuged sample result. 
The results are tabulated in table – 10. 
Acceptance criteria: 
     The percentage difference between centrifuged and filtered sample results is not more than 
± 2.0 with respect to centrifuged sample results. 
FILTER INTERFERENCE STUDY 
Table – 10 
 
Sample Name 
 
Percentage Assay 
 
Percentage Difference 
 
Centrifuged sample 
 
101.9 
 
- 
 
Filtered sample 
 
101.8 
 
0.1 
 
CONCLUSION: 
      The percentage difference value within the acceptance limit for filtered sample. Hence 
0.45µm nylon filters suitable for filtering the sample solution of dexibuprofen tablets. 
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3.9 ROBUSTNESS: 
      Robustness of the method verified by deliberately varying the following instrumental 
conditions. 
a) By changing the flow rate by ± 10%. 
b) By changing the wavelength by ± 2 nm. 
c) By changing the organic content in mobile phase by ± 2% absolute. 
d) By changing the mobile phase pH by ± 0.2 units. 
System suitability was evaluated in each condition and 300 mg tablet sample was 
analysed in triplicate. The results were compared with the method precision data and 
tabulated in table – 11. 
ACCEPTANCE CRITERIA: 
     Overall percentage relative standard deviation (%RSD) for assay of each change 
condition and method precision results is not more than ± 2.0. 
ROBUSTNESS 
TABLE - 11 
SL. No 
 
Minus 
wavelength 
(218 nm) 
Plus 
wavelength 
(222 nm) 
 
Minus flow 
rate (0.9 
ml/min) 
Plus flow 
rate (1.1 ml/ 
min) 
Minus 
organic 
(58%) 
 
Plus 
organic     
(62% ) 
Minus  
pH (4.8) 
 
Plus 
pH(5.2) 
1 
 
98.6 98.6 100.9 99.2 98.4 98.3 98.2 98.1 
2 
 
98.5 98.5 100.2 99.3 101.3 100.7 100.8 100.2 
3 
 
100.3 100.1 101.2 98.8 101.2 101.3 100.7 99.9 
Overall 
Mean 
 
 
100.4 
 
100.4 
 
101.0 
 
100.4 
 
100.8 
 
100.7 
 
100.7 
 
100.5 
Overall 
% 
RSD 
 
1.8 
 
1.8 
 
1.5 
 
1.8 
 
1.7 
 
1.7 
 
1.7 
 
1.8 
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CONCLUSION: 
The method is robust for change in flow rate, change in organic content in mobile phase, 
change in buffer pH and change in wave length. 
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                  Table: 12 Results of Assay Method Validation of Dexibuprofen Tablets 
 
S.N0 
 
Parameters 
 
Observation 
 
Acceptance Criteria 
 
Passes/ Fail 
1. 
 
1.1 
1.2 
1.3 
Precision 
 
System Precision 
Method Precision 
Intermediate Precision 
 
 
0.3 
1.8 
1.3 
 
Percentage relative 
standard deviation 
(%RSD) is not more than 
2.0 
 
Passes 
 
2. 
 
Specificity 
 
No peak elute 
 
No peak elutes at the 
retention time of main 
peak in the blank and 
placebo 
 
Passes 
 
 
 
 
 
3. 
Forced Degradation 
 
a. Degradation By       
Hydrochloric Acid 
b. Degradation By 
Sodium Hydroxide 
c. Degradation By 
Hydrogen Per- Oxide 
d. Degradation by 
Thermal Heat. 
e. Degradation By 
Exposing Light 
 
 
10.9 
 
2.1 
 
1.8 
 
21.0 
 
1.0 
 
 
 
 
 
Degradation is not more 
than 30 % in each 
condition 
 
 
 
 
 
 
Passes 
 
4. 
 
Linearity 
 
0.9999 
Correlation coefficient  is 
not less than 0.99 
 
Passes 
 
5. 
 
Accuracy 
The percentage  recovery 
was found between 99.80 
– 100.27% 
The percentage  
Recovery at each level is 
between 98.0-102.0% 
 
Passes 
 
6. 
 
Solution Stability 
 
Well within the limit 
 
 
 %RSD is not more than 
2.0 
 
Passes 
 
7. 
 
Filter Interference 
 
0.1 
The percentage 
difference is not more 
than 2.0 
 
Passes 
 
8. 
 
Robustness 
Well within the limit Overall percentage 
Relative standard 
deviation  (%RSD) is not 
more than 20 
 
 
Passes 
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METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF 
DEXIBUPROFEN IN TABLET DOSAGE FORM BY HPTLC 
HPTLC METHOD DEVELOPMENT:  
¾ For HPTLC analysis, initially various mobile phase and stationary phases were tried in 
attempts to obtain the best separation and resolution of Dexibuprofen. 
¾ The mobile phase consisting Toluene: Ethyl acetate: Glacial acetic acid in the 
proportion of (6: 3: 1% v/v/v) selected that gave satisfactory separation and gave well 
resolved peaks for Dexibuprofen. 
¾ Dexibuprofen exhibit significant absorbance at a wavelength 254nm was selected as a 
detection wavelength for the determination of dexibuprofen. 
¾ Well defined spots were obtained when the chamber was saturated with mobile phase 
for 15 min ensures good reproducibility and peak shape. The Rf value for 
Dexibuprofen was 0.83±0.02. 
¾ The Dexibuprofen showed good linearity in the range of 1-5 µg per spot with 
coefficient of correlation value 0.9994 for peak area. (chromatogram for Dexibuprofen 
and linearity densitogram was shown in fig: 18 – 18.11.) 
¾ Spotted 3μg of Dexibuprofen sample solution allowed to develop in appropriate 
mobile phase and detect the spots as described. From the peak area recorded the 
amount of the drug in the formulation was determined (Table: 13). 
 
Table -13 Analysis of Formulations 
S.No. Drug  
Label 
Claim(mg) 
Amount 
found  
(mg) 
Assay %RSD 
 
1. 
 
Dexibupropfen 300 296.85 98.95±0.69 
  
 
 
                                                                                   Result And Discussion 
 
Department Of Pharmaceutical Analysis, RVS College Of Pharmaceutical Sciences Page 87 
 
METHOD VALIDATION:  
After method development, the validation of the current method has been performed. 
The objective of method validation is to demonstrate that the method is suitable for its 
intended purpose as it is stated in ICH guidelines. The method was validated for linearity, 
accuracy, precision. 
1. Linearity:  
For linearity study, aliquots of 1.0, 2.0, 3.0, 4.0, and 0.5 μg  from Dexibuprofen 
standard stock solution was applied on TLC. The plates were developed,  dried and scanned 
densitometrically at 254 nm. The drug peak-area was calculated for each concentration level 
and a graph was plotted of drug concentration against the peak area and shown in              
(Table: 14, Fig.18.12). Calibration parameters are given in Table: 15. 
                           
                                Table - 14:  Linearity of Dexibuprofen  
 
 
 
SL. No 
Standard 
concentration 
µg/ spot 
Peak Area 
1 1.0 425.3 
2 2.0 874.3 
3 3.0 1231.6 
4 4.0 1656.2 
5 5.0 2143.0 
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                          Table -15 Calibration Parameters for DEXIBUPROFEN  
Parameters 
 
Dexibuprofen 
Linearity Range(µg/Spot) 
 
1-5 
Slope 
 
400.49 
Intercept 0.89 
 
Regression Co-Efficient 
 
0.9994 
 
 
2. Accuracy:  
The proposed method when used for extraction and subsequent estimation of drug 
from tablet dosage form after over spotting with 80, 100 and 120 % of additional drug; mean 
recovery is within acceptable limits, indicating the method is accurate and afforded recovery 
of 98.82 – 99.69 %. It showed very low % RSD of peak area of Dexibuprofen (Table: 16). 
    
                                Table -16: Recovery studies for Dexibuprofen (n=3) 
 
Label claim 
(mg / tablet) 
 
Recovery level    
 
Amount added 
(mg) 
 
Amount 
recovered (mg) ± 
% RSD 
 
% Recovery 
300 80 240 238.16±0.42 98.82 
300 100 300 298.68±0.85 98.67 
300 120 360 358.90±0.59 99.69 
 
3. Precision:  
The repeatability and intermediate precision were studied (Table-3 and -4 respectively). 
Repeatability It showed very low % RSD values of intra-day and inter-day are in range of 
0.13 to 1.6 and 0.24 to 1.6, Dexibuprofen respectively. The results were shown in Table-17, 
17a, and 17b. 
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                                       Table – 17:  Precision of Dexibuprofen 
 
S. No 
 
 
Concentration 
(µg/ spot) 
 
Peak Area 
1. 3 1212.1 
2. 3 1218.4 
3. 3 1209.6 
4. 3 1188.4 
5. 3 1211.8 
6. 3 1203.5 
 
Mean 
 
- 
 
1207.3 
 
Percentage Relative 
Standard Deviation 
 
- 
 
0.86 
 
 
                                   Table – 17a: Intra-day Precision of Dexibuprofen 
 
 
S. No 
 
Concentration 
(µg / spot) 
 
Area 
 
Mean 
 
Standard 
Deviation 
 
% RSD 
1. 
2. 
3. 
1 
1 
1 
411.3 
400.9 
398.9 
 
403.7 
 
 
6.65 
 
1.6 
1. 
2. 
3. 
3 
3 
3 
1213.9 
1210.3 
1211.6 
 
1211.9 
 
1.8 
 
0.15 
1. 
2. 
3. 
5 
5 
5 
2146.2 
      2143.9 
2149.8 
 
2146.6 
 
2.9 
 
0.13 
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Table – 17b: Inter-day Precision of Dexibuprofen 
 
S. No Concentration 
(µg / spot) 
Area Mean Standard 
Deviation 
% RSD 
1. 
2. 
3. 
1 
1 
1 
400.4 
399.6 
397.3 
 
399.1 
 
 
1.6 
 
0.40 
1. 
2. 
3. 
3 
3 
3 
1205.1 
1201.3 
1198.3 
 
1201.5 
 
3.40 
 
0.28 
1. 
2. 
3. 
5 
5 
5 
2140.7 
      2141.5 
2146.6 
 
2142.9 
 
         3.2 
 
0.14 
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            Table – 18 DEXIBUPROFEN HPTLC VALIDATION PARAMETERS 
 
S.No 
 
 
Parameters 
 
Dexibuprofen 
 
1. 
 
Rf 
 
0.83±0.008 
 
2. 
 
Linearity (µg/ spot) 
 
 
1 – 5 
 
3. 
 
Correlation coefficient (r2) 
 
 
0.9994 
 
4. 
 
Accuracy (% Recovery) 
 
(n = 3) %RSD 
 
1. 80 % 
2. 100% 
3. 120% 
 
 
 
 
 
 
98.82±0.42 
98.67±0.85 
99.69±0.59 
 
5. 
 
Precision (%RSD, n = 6) 
 
Intra-day( n = 3) (%RSD) 
 
Inter-day ( n = 3) (%RSD) 
 
0.86 
 
0.17 – 1.5 
 
0.13 – 1.6 
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                                                              9. CONCLUSION 
 In the present study a validated isocratic HPLC method has been developed for the 
determination of Dexibuprofen in tablet dosage forms. The analytical procedure is validated 
as per ICH guidelines and shown to be accurate, precise and specific. The mobile phase and 
the sample preparation are simple and the analysis time is short to prepare. The recoveries in 
formulations were in good agreement with their respective label claims. Its chromatographic 
run time of 10 min allows the analysis of a large number of samples in a short period of time. 
Therefore, it is suitable for the routine analysis of Dexibuprofen in tablet dosage forms. The 
simplicity of the method allows for application in laboratories that lack sophisticated 
analytical instruments such as LC-MS/MS or GC-MS/MS that are complicated, costly, and 
time consuming rather than a simple HPLC method. 
 The result of analysis of Dexibuprofen tablet dosage forms by the proposed HPTLC 
method was developed and validated as per ICH guidelines and the method was found to be 
simple, precise, accurate and highly reproducible, reliable thus can be used for determination 
of Dexibuprofen. The present recovery obtained was 98.82 – 99.69 % indicates no 
interference from the common excipients in the tablet formulations. This method can be used 
for the routine analysis of the Dexibuprofen in tablet dosage form. 
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